http://orcid.org/0000-0002-6734-5674
References
- Dalvie DK, Kalgutkar AS, Khojasteh-Bakht SC, et al. (2002). Biotransformation reactions of five-membered aromatic heterocyclic rings. Chem Res Toxicol 15:269–99.
- Derfuss T, Mehling M, Papadopoulou A, et al. (2020). Advances in oral immunomodulating therapies in relapsing multiple sclerosis. Lancet Neurol.
- EMA (European Medicines Agency) Committee for Human Medicinal Products (CHMP) (2005). Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function, CPMP/EWP/2339/02.
- EMA (European Medicines Agency) Committee for Human Medicinal Products (CHMP) (2015). Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function, EMA/CHMP/83874/2014.
- Faissner S, Gold R. (2018). Efficacy and safety of the newer multiple sclerosis drugs approved since 2010. CNS Drugs 32:269–87.
- FDA (Food and Drug Administration) United States Department of Health and Human Services, Center for Drug Evaluation and Research (2016). Safety testing of drug metabolites.
- FDA (Food and Drug Administration) United States Department of Health and Human Services, Center for Drug Evaluation and Research (CDER) (2017). In vitro metabolism- and transporter-mediated drug-drug interaction studies.
- Graham RA, Lum BL, Morrison G, et al. (2011). A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry. Drug Metab Dispos 39:1460–7.
- Gu C, Elmore CS, Lin J, et al. (2012). Metabolism of a G protein-coupled receptor modulator, including two major 1,2,4-oxadiazole ring-opened metabolites and a rearranged cysteine-piperazine adduct. Drug Metab Dispos 40:1151–63.
- Hamilton RA, Garnett WR, Kline BJ. (1981). Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408–13.
- Hermann V, Batalov A, Smakotina S, et al. (2019). First use of cenerimod, a selective S1P1 receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study. Lupus Sci Med 6:e000354.
- ICRP (International Commission on Radiological Protection) (2007). The 2007 Recommendations of the International Commission on Radiological Protection. ICRP Publication 103. Ann ICRP 37:1–332.
- Juif PE, Baldoni D, Reyes M, et al. (2017). Pharmacokinetics, pharmacodynamics, tolerability, and food effect of cenerimod, a selective S1P1 receptor modulator in healthy subjects. Int J Mol Sci 18:2636–51.
- Juif PE, Kraehenbuehl S, Dingemanse J. (2016). Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulators. Expert Opin Drug Metab Toxicol 12:879–95.
- Kifuji T, Inoue S, Furukawa M, et al. (2019). Absorption, disposition and metabolic pathway of amiselimod (MT-1303) in healthy volunteers in a mass balance study. Xenobiotica 49:1033–43.
- Lan SJ, Weliky I, Schreiber EC. (1973). Metabolic studies with trans-5-amino-3-(2-(5-nitro-2-furyl)vinyl)-1,2,4-(5- 14 C)oxadiazole (SQ 18,506). 1. Reductive cleavage of the 1,2,4-oxadiazole ring. Xenobiotica 3:97–102.
- Penner N, Klunk LJ, Prakash C. (2009). Human radiolabeled mass balance studies: objectives, utilities and limitations. Biopharm Drug Dispos 30:185–203.
- Piali L, Birker-Robaczewska M, Lescop C, et al. (2017). Cenerimod, a novel selective S1P1 receptor modulator with unique signaling properties. Pharmacol Res Perspect 5:e00370.
- Roffey SJ, Obach RS, Gedge JI, et al. (2007). What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev 39:17–43.
- Thangada S, Khanna KM, Blaho VA, et al. (2010). Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics. J Exp Med 207:1475–83.
- Tintore M, Vidal-Jordana A, Sastre-Garriga J. (2019). Treatment of multiple sclerosis - success from bench to bedside. Nat Rev Neurol 15:53–8.
- Zhang D, Raghavan N, Chen SY, et al. (2008). Reductive isoxazole ring opening of the anticoagulant razaxaban is the major metabolic clearance pathway in rats and dogs. Drug Metab Dispos 36:303–15.
- Zollinger M, Gschwind HP, Jin Y, et al. (2011). Absorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: a case of xenobiotic biotransformation following endogenous metabolic pathways. Drug Metab Dispos 39:199–207.